An integrated insulin company, built on our own science.
BioGenomics Limited was founded in 2002 by scientists with long experience in drug development, regulatory science and GMP manufacturing. We develop, manufacture and supply biosimilar insulin analogues and recombinant proteins.
Founded in India by scientists
Our insulin aspart in use by patients in India, as InsuQuick™
Insulin aspart mix approved in India
Insulin glargine: Phase III completed; approved by the SEC
We built every step ourselves: the strains that express our insulin, the processes that purify it, the methods that prove its quality, and the formulations that become the finished cartridge, pen or vial.
Our insulin aspart has been used by patients in India since November 2023 under the brand name of InsuQuick™. Our insulin aspart mix was approved in India in September 2025. Our insulin glargine has completed Phase III and has been approved by the Subject Expert Committee (SEC).
How the pieces fit.
Strain and cell bank
Drug substance
India
Drug product
India and Oman
Regulatory dossier
Our partner
The person who needs insulin
What we stand for.
Our vision
Increasing access to life-saving biopharmaceuticals through adaptive innovations.
Our mission
To be a globally respected anti-diabetic biopharma brand by generating value for all its stakeholders.
Our values
Compassionate science
We pair technical precision with care for the people our work serves.
Responsible innovation
Every advance is guided by safety, quality and real need.
Unwavering quality
People who rely on insulin every day deserve nothing less than global standards.
Accessible excellence
Good science should reach everyone who needs it.
Transparency and trust
We are open about our processes, our progress and our commitments.
Insulin should not be a luxury.
Around 589 million adults worldwide live with diabetes, and many of them depend on insulin every day. Modern insulin analogues give better control and more flexibility in daily life. Yet for many people, and for many health systems, their cost remains a barrier.
We exist to lower that barrier. Because we built our technology ourselves and make our own drug substance, we can supply modern insulin analogues at a price health systems can sustain.
Source: International Diabetes Federation, IDF Diabetes Atlas, 11th edition (2025).
Access depends on more than price. It needs three things, and we commit to all three:
Reliable supply.
A person on insulin cannot wait for a shortage to resolve.
Consistent quality.
Every cartridge must be one a doctor can trust.
A sustainable price.
One that health systems can afford year after year.
India’s first launched biosimilar insulin aspart.
In 2023, USV Private Limited and BioGenomics launched InsuQuick™, India’s first launched biosimilar rapid-acting insulin aspart. We developed it with 100% indigenous technology, backed by more than 10 years of our own R&D.
Our own R&D
We built the technology for rapid-acting insulin aspart ourselves, and the expertise to make complex biologics.
Regulatory permission
India’s drug regulator granted permission for our domestically developed insulin aspart.
Launch in India
USV and BioGenomics launched InsuQuick™.
Three presentations
Cartridges, vials and prefilled disposable pens.
Why it mattered. It strengthened India’s own biotechnology, widened treatment choice and competition in mealtime insulin, and showed that Indian companies can develop complex biologic medicines, in line with Make in India.
“Insulin is not a cure for diabetes; it is a treatment.”
Dr. Frederick Banting, co-discoverer of insulin · Nobel Lecture, 1925
The people who lead BioGenomics.
Dr. Sanjay Sonar
President and Co‑founder
Dr. Sonar has over 35 years of experience in protein engineering and downstream processing. He earned his Ph.D. at the Indian Institute of Technology Bombay and did postdoctoral work at Boston University and at MIT, where he worked for six years with Nobel Laureate Har Gobind Khorana. He is an inventor on more than 100 patents.
“The work matters only when it reaches the people who need it.”
Dr. Archana Rajesh Krishnan
Whole-time Director and Co‑founder
Dr. Krishnan is a Co-founder and Director at BioGenomics and leads the scientific work in genetic engineering, cloning, fermentation, and biological assays, with a core focus on translating innovative research into commercially viable biologics. She has a deep understanding of scale-up for commercial manufacturing, with over 26 years of experience. Her journey began with a strong academic foundation in Microbiology and Biochemistry, culminating in a Ph.D. in Biotechnology. An accomplished inventor, Dr. Krishnan holds more than 27 patents and numerous publications in peer reviewed scientific journals.
“I am passionate about leading scientific innovation from the laboratory to commercial manufacturing.”
Abhishek Deshpande
Chief Financial Officer
Mr. Abhishek Deshpande brings 25 years of national and international management experience. A Chartered Accountant with management studies, he oversees the company’s business operations, balancing financial discipline with operational efficiency to support growth and long-term value.
A board with scientific, regulatory, financial and commercial depth.
Our board includes independent directors and directors nominated by our institutional shareholders.
Dr. Archana Krishnan
Whole-time Director and Co‑founder
Rajesh Dalal
Independent Director
Former Venture Partner, OrbiMed
Rajiv Malik
Independent Director
Former CEO, Eurofins Advinus
Mohammed Hamdan Al Rubaie
Nominee Director
Former Director General, Pharmaceutical Affairs and Drug Control, Ministry of Health, Oman
Ali Abdullah Ali Al Amri
Nominee Director
Healthcare Investments, Oman Investment Authority
Imran Jamiluddin Shaikh
Nominee Director
Healthcare Lead, Oman Investment Authority
Namit Rustagi
Nominee Director
Chief Legal Counsel, MB Group
Sushil Srivastava
Nominee Director
Former CFO, MB Holding